Q-omics provides the consensus-scored DEPDC1B profile across patient tissues and cancer cell-line models. DEPDC1B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DEPDC1B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DEPDC1B RNA expression shows 24,975 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where DEPDC1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEPDC1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEPDC1B survival associations across molecular data types. DEPDC1B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEPDC1B RNA expression–survival associations across cancer types. High DEPDC1B expression shows unfavorable associations in KIRP, MESO, KICH, UVM, LIHC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DEPDC1B RNA expression.
This table summarizes DEPDC1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DEPDC1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEPDC1B shows higher tumor expression in HNSC, LUAD, BLCA, THCA, LIHC and COAD. The HNSC box plot shows higher DEPDC1B RNA expression in tumor versus normal tissue (log2 FC = +1.704, t-test p < 0.001).
This table shows molecular features associated with DEPDC1B in patient tissues and cancer cell lines. In patient samples, DEPDC1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DEPDC1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
